Tag: IGI
Ichnos Glenmark Innovation and AbbVie announce exclusive global licensing agreement for...
IGI’s lead investigational asset, ISB 2001, has been developed using IGI’s proprietary BEAT® protein platform, for oncology and autoimmune diseases